激素难治性前列腺癌姑息治疗的进展
Update in palliative management of hormone refractory cancer of prostate.
作者信息
Singh Pratipal, Srivastava Aneesh
机构信息
Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
出版信息
Indian J Urol. 2007 Jan;23(1):43-50. doi: 10.4103/0970-1591.30266.
Abstract
Hormone refractory prostate cancer (HRPC) is an incurable disease and as in the pressure sensitive adhesive era the median survival of patients is increasing, these men increasingly develop symptomatic problems as a result of advanced local and or metastatic disease during their progression to death. Recently, it has been shown that it is possible to improve survival in this group of patients with use of chemotherapy which reinforces the need of better options in palliative care. We discus the various clinical problems (Part I) and treatment options of palliative care (Part II) and try to formulate an action plan in this review.
摘要
激素难治性前列腺癌（HRPC）是一种无法治愈的疾病，在压敏胶粘剂时代，患者的中位生存期在增加，这些男性在病情进展至死亡期间，由于局部晚期和/或转移性疾病，越来越多地出现症状性问题。最近的研究表明，使用化疗有可能提高这组患者的生存率，这凸显了在姑息治疗中需要更好选择的必要性。在本综述中，我们讨论了各种临床问题（第一部分）和姑息治疗的选择（第二部分），并试图制定一个行动计划。
相似文献
1
Update in palliative management of hormone refractory cancer of prostate.激素难治性前列腺癌姑息治疗的进展
Indian J Urol. 2007 Jan;23(1):43-50. doi: 10.4103/0970-1591.30266.
2
Chemotherapy for hormone-refractory prostate cancer.激素难治性前列腺癌的化疗
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005247. doi: 10.1002/14651858.CD005247.pub2.
3
Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.激素难治性前列腺癌（HRPC）：当前及未来的治疗方法
Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):11-34.
4
Second-line chemotherapy for advanced hormone-refractory prostate cancer.晚期激素难治性前列腺癌的二线化疗
Clin Adv Hematol Oncol. 2008 Feb;6(2):118-22, 127-32.
5
Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?铂类化疗在激素难治性前列腺癌患者的治疗中是否有作用？
Cancer. 2007 Feb 1;109(3):477-86. doi: 10.1002/cncr.22439.
6
Treatment options in hormone-refractory metastatic prostate carcinoma.激素难治性转移性前列腺癌的治疗选择
Tumori. 2004 Nov-Dec;90(6):535-46. doi: 10.1177/030089160409000601.
7
Management of the spectrum of hormone refractory prostate cancer.激素难治性前列腺癌谱系的管理
Eur Urol. 2006 Sep;50(3):428-38; discussion 438-9. doi: 10.1016/j.eururo.2006.05.017. Epub 2006 Jun 2.
8
Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.激素难治性前列腺癌伴转移男性患者的非激素全身治疗：安大略癌症护理循证护理项目泌尿生殖系统癌症疾病部位组的系统评价
BMC Cancer. 2006 May 2;6:112. doi: 10.1186/1471-2407-6-112.
9
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.沙他铂治疗激素难治性转移性前列腺癌。
Ther Clin Risk Manag. 2007 Oct;3(5):877-83.
10
Surgical Decompression of High-Grade Spinal Cord Compression from Hormone Refractory Metastatic Prostate Cancer.手术减压治疗激素难治性转移性前列腺癌引起的高分级脊髓压迫症
Neurosurgery. 2018 May 1;82(5):670-677. doi: 10.1093/neuros/nyx292.
引用本文的文献
1
Management of bleeding in palliative care patients in the general internal medicine ward: a systematic review.普通内科病房姑息治疗患者出血的管理：一项系统综述。
Ann Med Surg (Lond). 2019 Dec 18;50:14-23. doi: 10.1016/j.amsu.2019.12.002. eCollection 2020 Feb.
本文引用的文献
1
Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer.生活质量作为转移性激素难治性前列腺癌患者发病和死亡的潜在预测指标。
Qual Life Res. 2006 Oct;15(8):1297-306. doi: 10.1007/s11136-006-0003-2. Epub 2006 Aug 10.
2
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.骨相关事件对转移性前列腺癌患者健康相关生活质量的意义。
Ann Oncol. 2005 Apr;16(4):579-84. doi: 10.1093/annonc/mdi122. Epub 2005 Feb 25.
3
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.多西他赛联合泼尼松或米托蒽醌联合泼尼松用于晚期前列腺癌治疗
N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720.
4
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.前列腺特异性抗原时代激素难治性前列腺癌患者的生存情况
J Urol. 2004 Apr;171(4):1525-8. doi: 10.1097/01.ju.0000118294.88852.cd.
5
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.接受雄激素剥夺治疗的前列腺癌男性患者的骨质疏松症：诊断和治疗建议
Cancer. 2004 Mar 1;100(5):892-9. doi: 10.1002/cncr.20056.
6
Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.姑息性经尿道前列腺切除术治疗局部晚期前列腺癌患者的膀胱出口梗阻
J Urol. 2004 Feb;171(2 Pt 1):668-71. doi: 10.1097/01.ju.0000104845.24632.92.
7
Rectal infiltration by prostatic adenocarcinoma: report on six patients and review of the literature.前列腺腺癌的直肠浸润：6例病例报告及文献复习
Ann R Coll Surg Engl. 2003 Nov;85(6):382-5. doi: 10.1308/003588403322520726.
8
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.预测激素难治性转移性前列腺癌男性患者生存率的预后模型。
J Clin Oncol. 2003 Apr 1;21(7):1232-7. doi: 10.1200/JCO.2003.06.100.
9
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.唑来膦酸治疗激素难治性转移性前列腺癌患者的一项随机、安慰剂对照试验。
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. doi: 10.1093/jnci/94.19.1458.
10
Skeletal fractures negatively correlate with overall survival in men with prostate cancer.在前列腺癌男性患者中，骨骼骨折与总生存率呈负相关。
J Urol. 2002 Sep;168(3):1005-7. doi: 10.1016/S0022-5347(05)64561-2.
Zotero 插件